2026 Global: Nuclear Medicine/Radiopharmaceuticals Market-Competitive Review (2032) report
Description
The 2026 Global: Nuclear Medicine/Radiopharmaceuticals Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Curium, a leading global radiopharmaceutical company, supplies diagnostic imaging and targeted radiopharmaceutical therapies from its headquarters in Stockholm, Sweden. The company operates a broad portfolio of PET and SPECT agents and maintains manufacturing, distribution, and quality networks across Europe, North America, and Asia to support hospitals, clinics, and research institutions. Lantheus Medical Imaging, headquartered in North Billerica, United States, is a major US-based supplier of diagnostic radiopharmaceuticals, with a strong presence in the production and distribution of Tc-99m generators, FDG, and other tracers used in oncology, cardiology, and neurology. Novartis Advanced Accelerator Applications, based in Basel, Switzerland, contributes substantially to the market with radiopharmaceutical products such as Lutathera and Pluvicto, backed by Novartis' global development and commercialization platform and regulatory expertise. Together, these firms shape supply chains for diagnostic radiopharmaceuticals, isotopes, and related services, sustaining patient access to imaging and targeted therapy across multiple regions. They operate worldwide today.
Bayer, headquartered in Leverkusen, Germany, has a long-standing role in nuclear medicine, offering imaging agents, radiopharmaceuticals, and companion diagnostics that support diagnostic and therapeutic workflows across diverse indications. Jubilant Life Sciences, headquartered in Noida, India, is a prominent radiopharmaceutical supplier with production facilities for Tc-99m generators, cold kits, and select imaging tracers, serving markets in Asia, Europe, and North America through integrated manufacturing and distribution networks. IBA, headquartered in Louvain-la-Neuve, Belgium, is a leading developer of cyclotron systems and radiopharmaceutical production solutions, enabling on-site synthesis and distribution of PET tracers in major regional hubs. Telix Pharmaceuticals, headquartered in Melbourne, Australia, focuses on radiopharmaceuticals for imaging and targeted therapy, advancing products such as PSMA or other receptor-targeted tracers, with clinical development and commercial activities spanning Asia-Pacific, Europe, and North America. These firms collectively drive growth in imaging accuracy, therapeutic radiopharmaceuticals, and access to advanced nuclear medicine worldwide. They enable cross-border access.
Nordion, headquartered in Ottawa, Canada, remains a central supplier of medical isotopes and radiopharmaceutical components that underpin PET tracer production, imaging workflows, and radiopharmaceutical manufacturing across North America. Cardinal Health, headquartered in Dublin, Ohio, United States, is a major distributor and service provider for radiopharmaceutical products, offerings that include kit production, logistics, and regulatory support that enable hospital-based nuclear medicine programs. Siemens Healthineers, headquartered in Erlangen, Germany, supplies imaging equipment, software, and associated radiopharmaceutical services that support PET and SPECT applications, complementing radiopharmaceutical manufacturers with integrated solutions across diagnostic and therapeutic pathways. Together, these three firms provide essential capital, distribution, and service ecosystems that sustain nuclear medicine's global reach and clinical impact. Their collaborations underwrite isotope production capacity, regulatory compliance, and cross-border supply reliability essential for patient care. Sustained investment in infrastructure, safety, and analytics continues to expand access to targeted diagnostics and radiopharmaceutical therapies worldwide. This market remains dynamic.
Curium, a leading global radiopharmaceutical company, supplies diagnostic imaging and targeted radiopharmaceutical therapies from its headquarters in Stockholm, Sweden. The company operates a broad portfolio of PET and SPECT agents and maintains manufacturing, distribution, and quality networks across Europe, North America, and Asia to support hospitals, clinics, and research institutions. Lantheus Medical Imaging, headquartered in North Billerica, United States, is a major US-based supplier of diagnostic radiopharmaceuticals, with a strong presence in the production and distribution of Tc-99m generators, FDG, and other tracers used in oncology, cardiology, and neurology. Novartis Advanced Accelerator Applications, based in Basel, Switzerland, contributes substantially to the market with radiopharmaceutical products such as Lutathera and Pluvicto, backed by Novartis' global development and commercialization platform and regulatory expertise. Together, these firms shape supply chains for diagnostic radiopharmaceuticals, isotopes, and related services, sustaining patient access to imaging and targeted therapy across multiple regions. They operate worldwide today.
Bayer, headquartered in Leverkusen, Germany, has a long-standing role in nuclear medicine, offering imaging agents, radiopharmaceuticals, and companion diagnostics that support diagnostic and therapeutic workflows across diverse indications. Jubilant Life Sciences, headquartered in Noida, India, is a prominent radiopharmaceutical supplier with production facilities for Tc-99m generators, cold kits, and select imaging tracers, serving markets in Asia, Europe, and North America through integrated manufacturing and distribution networks. IBA, headquartered in Louvain-la-Neuve, Belgium, is a leading developer of cyclotron systems and radiopharmaceutical production solutions, enabling on-site synthesis and distribution of PET tracers in major regional hubs. Telix Pharmaceuticals, headquartered in Melbourne, Australia, focuses on radiopharmaceuticals for imaging and targeted therapy, advancing products such as PSMA or other receptor-targeted tracers, with clinical development and commercial activities spanning Asia-Pacific, Europe, and North America. These firms collectively drive growth in imaging accuracy, therapeutic radiopharmaceuticals, and access to advanced nuclear medicine worldwide. They enable cross-border access.
Nordion, headquartered in Ottawa, Canada, remains a central supplier of medical isotopes and radiopharmaceutical components that underpin PET tracer production, imaging workflows, and radiopharmaceutical manufacturing across North America. Cardinal Health, headquartered in Dublin, Ohio, United States, is a major distributor and service provider for radiopharmaceutical products, offerings that include kit production, logistics, and regulatory support that enable hospital-based nuclear medicine programs. Siemens Healthineers, headquartered in Erlangen, Germany, supplies imaging equipment, software, and associated radiopharmaceutical services that support PET and SPECT applications, complementing radiopharmaceutical manufacturers with integrated solutions across diagnostic and therapeutic pathways. Together, these three firms provide essential capital, distribution, and service ecosystems that sustain nuclear medicine's global reach and clinical impact. Their collaborations underwrite isotope production capacity, regulatory compliance, and cross-border supply reliability essential for patient care. Sustained investment in infrastructure, safety, and analytics continues to expand access to targeted diagnostics and radiopharmaceutical therapies worldwide. This market remains dynamic.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
